L. Mungapen

The economic impact of overactive bladder syndrome in six Western countries

C. Kelleher, P. Reeves, D. Irwin, 2009, BJU international.

Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.

D. Price, A. Gray, R. Gale, 2011, Respiratory medicine.

P84 Utility Values For COPD Patients Based on the EQ-5D Questionnaire from Three Indacaterol Phase III Studies

Y. Asukai, L. Mungapen, M. Baldwin, 2012, Thorax.

Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling

Alastair Gray, David Price, Yumi Asukai, 2013, PharmacoEconomics.

Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching

Laura Mungapen, P. Kefalas, L. Mungapen, 2019, Journal of market access & health policy.

The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System.

M. Kraemer, Y. Asukai, P. Thuresson, 2012, Value in health regional issues.

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy

P. Kefalas, L. Mungapen, Matthew B Durdy, 2018, Journal of market access & health policy.